지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.1
- 수록면
- 305 - 309 (5page)
이용수
초록· 키워드
오류제보하기
Purpose: We conducted a prospective single-center study to evaluate the possibility of discontinuation of dutasteride after combination therapy with an alpha blocker for benign prostatic hyperplasia (BPH).
Materials and Methods: We prospectively treated BPH patients with an alpha blocker and dutasteride (0.5 mg/d). Patients who had been treated with alpha blockers against BPH for more than 2 months were eligible, and 20 patients were included in the study. After 6 months of combination therapy, dutasteride was discontinued. Patients were followed for 12 months after cessation. Prostate volume, intraprostatic architecture determined by transrectal ultrasound, peak urinary flow rate, postvoid residual urine volume, and the serum prostate-specific antigen level were evaluated every 6 months, and the International Prostate Symptom Score and overactive bladder symptom score (OABSS) every 3 months. Patients were allowed to restart dutasteride during the follow-up period according to their desire.
Results: Twelve patients (12/20, 60%) restarted the combination therapy from 6 to 12 months into the follow-up period. For patients who restarted dutasteride, the prostate volume and OABSS had increased and worsened after discontinuation, respectively. A visible transition zone with a clear border on transrectal ultrasound at baseline and regrowth of the prostate after discontinuation of dutasteride were risk factors for restarting the therapy (Mann-Whitney U test: p=0.008, p=0.017).
Conclusions: Prostatic enlargement after discontinuation of dutasteride differs among patients. Rapid regrowth of the prostate leads to deterioration of storage symptoms and a tendency to restart dutasteride. Baseline intraprostatic architecture may be a predictive factor for whether the patient is a good candidate for discontinuation.
목차
등록된 정보가 없습니다.
참고문헌 (10)
참고문헌 신청
Wu XJ / 2014 / Dutasteride on benign prostatic hyperplasia: a meta-analysis on randomized clinical trials in 6460 patients / Urology 83:539~543
Roehrborn CG / 2011 / Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics:4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial / BJU Int 107:946~954
Roehrborn CG / 2014 / Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study / BJU Int 113:623~635
Masumori N / 2003 / Natural history of lower urinary tract symptoms in men: result of a longitudinal community-based study in Japan / Urology 61:956~960
Barkin J / 2003 / Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride / Eur Urol 44:461~466
Roehrborn CG / 2011 / Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics:4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial / BJU Int 107:946~954
Roehrborn CG / 2014 / Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study / BJU Int 113:623~635
Masumori N / 2003 / Natural history of lower urinary tract symptoms in men: result of a longitudinal community-based study in Japan / Urology 61:956~960
Barkin J / 2003 / Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride / Eur Urol 44:461~466
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Cerebral Venous Sinus Thrombosis Associated with Dutasteride Use
Yonsei Medical Journal
2020 .01
-
Effect of Alpha-Blockers on Patients with Benign Prostatic Hyperplasia with Inflammatory Cells in the Prostatic Fluid
Urogenital Tract Infection
2018 .01
-
Patient’s Factors Correlated with Prostate Volume Recovery after 5 Alpha Reductase Inhibitor Discontinuation
Urogenital Tract Infection
2018 .01
-
Clinical Course of the Benign Prostate Hyplasia Patients during the Intermittent Use of 5-Alpha Reductase Inhibitors
Urogenital Tract Infection
2019 .01
-
전립선비대증
대한의사협회지
2015 .01
-
Community-based research on the benign prostatic hyperplasia prevalence rate in Korean rural area
Investigative and Clinical Urology
2015 .01
-
Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker Therapy
International Neurourology Journal
2020 .01
-
Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia
Annals of Dermatology
2016 .01
-
Impact of birth season on second-to-fourth digit ratio, prostate volume, and prostate cancer
Investigative and Clinical Urology
2022 .03
-
Efficacy and safety of holmium laser enucleation of the prostate for extremely large prostatic adenoma in patients with benign prostatic hyperplasia
Investigative and Clinical Urology
2015 .01
-
Comprehensive Analysis of Individual Anatomical Structures for Micturition Symptoms and Maximum Flow Rate in Men With Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms
International Neurourology Journal
2023 .06
-
Clinical Significance of the Resistive Index of Prostatic Blood Flow According to Prostate Size in Benign Prostatic Hyperplasia
International Neurourology Journal
2016 .01
-
Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study
Investigative and Clinical Urology
2020 .01
-
Holmium Laser Enucleation of the Prostate is Safe for Patients Above 80 Years: A Prospective Study
International Neurourology Journal
2016 .01
-
Changes in Prevalence and Treatment Pattern of Benign Prostatic Hyperplasia in Korea
International Neurourology Journal
2021 .12
-
Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication
International Neurourology Journal
2016 .12
-
전립선암의 영상의학적 소견
대한의사협회지
2015 .01
-
Drug Prescription Patterns During Initial Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Study Based on Health Insurance Review and Assessment Database
Journal of Korean Medical Science
2022 .03
-
SRD5A2 Gene Polymorphisms and the Risk of Benign Prostatic Hyperplasia but not Prostate Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Early dutasteride monotherapy in men with detectable serum prostate-specific antigen levels following radical prostatectomy: A prospective trial
Investigative and Clinical Urology
2017 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0